Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 1815
1254
mi
from 91732
Lincoln, NE
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 1815
1254
mi
from 91732
Lincoln, NE
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 012
214
mi
from 91732
Las Vegas, NV
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 012
214
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 025
2432
mi
from 91732
New York, NY
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 025
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative site 084
1967
mi
from 91732
Columbus, OH
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative site 084
1967
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 236
1250
mi
from 91732
Tulsa, OK
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 236
1250
mi
from 91732
Tulsa, OK
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site
829
mi
from 91732
Portland, OR
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site
829
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 012
2176
mi
from 91732
Johnstown, PA
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 012
2176
mi
from 91732
Johnstown, PA
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 094
1313
mi
from 91732
Sioux Falls, SD
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 094
1313
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 13
1762
mi
from 91732
Nashville, TN
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 13
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site
1354
mi
from 91732
Houston, TX
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site
1354
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 045
1341
mi
from 91732
The Woodlands, TX
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 045
1341
mi
from 91732
The Woodlands, TX
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 019
594
mi
from 91732
Ogden, UT
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 019
594
mi
from 91732
Ogden, UT
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative site 100
568
mi
from 91732
Salt Lake City, UT
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative site 100
568
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 023
2133
mi
from 91732
Roanoke, VA
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 023
2133
mi
from 91732
Roanoke, VA
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site #027
961
mi
from 91732
Seattle, WA
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site #027
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 049
1729
mi
from 91732
Milwaukee, WI
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 049
1729
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated:  10/31/2013
Forest Investigative Site 204
mi
from 91732
Brussel,
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Status: Enrolling
Updated: 10/31/2013
Forest Investigative Site 204
mi
from 91732
Brussel,
Click here to add this to my saved trials
Intellectual Enrichment to Build Cognitive Reserve in MS
A Randomized Controlled Trial of Intellectual Enrichment to Build Cognitive Reserve in Multiple Sclerosis
Status: Enrolling
Updated:  11/6/2013
Kessler Foundation
mi
from 91732
West Orange, NJ
Intellectual Enrichment to Build Cognitive Reserve in MS
A Randomized Controlled Trial of Intellectual Enrichment to Build Cognitive Reserve in Multiple Sclerosis
Status: Enrolling
Updated: 11/6/2013
Kessler Foundation
mi
from 91732
West Orange, NJ
Click here to add this to my saved trials
Eye Movements and Reading Disabilities
Reliability of Clinical Eye Movement Tests as Screening Devices for Reading Disabilities
Status: Enrolling
Updated:  12/4/2013
Scripps Clinic
92
mi
from 91732
San Diego, CA
Eye Movements and Reading Disabilities
Reliability of Clinical Eye Movement Tests as Screening Devices for Reading Disabilities
Status: Enrolling
Updated: 12/4/2013
Scripps Clinic
92
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Baltimore VA Medical Center
2301
mi
from 91732
Baltimore, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Baltimore VA Medical Center
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Community Mental Health Centers
2301
mi
from 91732
Baltimore, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Community Mental Health Centers
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Keypoint Community Mental Health Centers
2307
mi
from 91732
Baltimore, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Keypoint Community Mental Health Centers
2307
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Keypoint Mental health Center
2306
mi
from 91732
Dundalk, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Keypoint Mental health Center
2306
mi
from 91732
Dundalk, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Maryland Psychiatric Research Center
2295
mi
from 91732
Baltimore, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Maryland Psychiatric Research Center
2295
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Maryland Psychiatric Research Center
2295
mi
from 91732
Catonsville, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Maryland Psychiatric Research Center
2295
mi
from 91732
Catonsville, MD
Click here to add this to my saved trials
SMART: Somatotrophics, Memory, and Aging Research Trial
GHRH: Cognition in Aging and MCI
Status: Enrolling
Updated:  12/17/2013
Univ of Washington
961
mi
from 91732
Seattle, WA
SMART: Somatotrophics, Memory, and Aging Research Trial
GHRH: Cognition in Aging and MCI
Status: Enrolling
Updated: 12/17/2013
Univ of Washington
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Mild Cognitive Impairment in Parkinson's Disease
A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease
Status: Enrolling
Updated:  12/17/2013
University of Pennsylvania, Ralston House
2375
mi
from 91732
Philadelphia, PA
Mild Cognitive Impairment in Parkinson's Disease
A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease
Status: Enrolling
Updated: 12/17/2013
University of Pennsylvania, Ralston House
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
University of Maryland
2301
mi
from 91732
Baltimore, MD
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
University of Maryland
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
The Zucker Hillside Hospital
2448
mi
from 91732
Glen Oaks, NY
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
The Zucker Hillside Hospital
2448
mi
from 91732
Glen Oaks, NY
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
Univ of North Carolina
2194
mi
from 91732
Chapel Hill, NC
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
Univ of North Carolina
2194
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia
Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia
Status: Enrolling
Updated:  12/20/2013
VA West Los Angeles Healthcare Center
25
mi
from 91732
Los Angeles, CA
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia
Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia
Status: Enrolling
Updated: 12/20/2013
VA West Los Angeles Healthcare Center
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
The Effects of a Carotenoid Intervention on Cognitive Function
The Effects of a Lutein + Zeaxanthin Intervention on Cognitive Function and Neural Efficiency
Status: Enrolling
Updated:  12/23/2013
University of Georgia
1974
mi
from 91732
Athens, GA
The Effects of a Carotenoid Intervention on Cognitive Function
The Effects of a Lutein + Zeaxanthin Intervention on Cognitive Function and Neural Efficiency
Status: Enrolling
Updated: 12/23/2013
University of Georgia
1974
mi
from 91732
Athens, GA
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Enhancement Center of America, Inc.
2431
mi
from 91732
Eatontown, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Enhancement Center of America, Inc.
2431
mi
from 91732
Eatontown, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Center of New Jersey, Inc.
2412
mi
from 91732
Monroe Twp, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Center of New Jersey, Inc.
2412
mi
from 91732
Monroe Twp, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Enhancement Center Of Nj, Inc.
2426
mi
from 91732
Toms River, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Enhancement Center Of Nj, Inc.
2426
mi
from 91732
Toms River, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Senior Adults Specialty Research
1212
mi
from 91732
Austin, TX
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Senior Adults Specialty Research
1212
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Clinica Santa Maria, Div Neurologia
mi
from 91732
Castellanza,
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Clinica Santa Maria, Div Neurologia
mi
from 91732
Castellanza,
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Enhancement Center of America, Inc.
2431
mi
from 91732
Eatontown, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Enhancement Center of America, Inc.
2431
mi
from 91732
Eatontown, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Center of New Jersey, Inc.
2412
mi
from 91732
Monroe Twp, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Center of New Jersey, Inc.
2412
mi
from 91732
Monroe Twp, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Memory Enhancement Center Of Nj, Inc.
2426
mi
from 91732
Toms River, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Memory Enhancement Center Of Nj, Inc.
2426
mi
from 91732
Toms River, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Senior Adults Specialty Research
1212
mi
from 91732
Austin, TX
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Senior Adults Specialty Research
1212
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated:  1/7/2014
Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze
6025
mi
from 91732
Milano,
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment
Status: Enrolling
Updated: 1/7/2014
Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze
6025
mi
from 91732
Milano,
Click here to add this to my saved trials
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Status: Enrolling
Updated:  1/21/2014
Pfizer Investigational Site
2485
mi
from 91732
New Haven, CT
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Status: Enrolling
Updated: 1/21/2014
Pfizer Investigational Site
2485
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Status: Enrolling
Updated:  1/21/2014
Pfizer Investigational Site
2485
mi
from 91732
West Haven, CT
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Status: Enrolling
Updated: 1/21/2014
Pfizer Investigational Site
2485
mi
from 91732
West Haven, CT
Click here to add this to my saved trials
Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)
Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI
Status: Enrolling
Updated:  3/7/2014
Atlanta VA Medical and Rehab Center, Decatur
1924
mi
from 91732
Decatur, GA
Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)
Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI
Status: Enrolling
Updated: 3/7/2014
Atlanta VA Medical and Rehab Center, Decatur
1924
mi
from 91732
Decatur, GA
Click here to add this to my saved trials
The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment
The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment (Kodro Solution)
Status: Enrolling
Updated:  3/13/2014
Mount Sinai Medical Center
2324
mi
from 91732
Miami Beach, FL
The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment
The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment (Kodro Solution)
Status: Enrolling
Updated: 3/13/2014
Mount Sinai Medical Center
2324
mi
from 91732
Miami Beach, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
HOPE Research Institute
346
mi
from 91732
Phoenix, AZ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
HOPE Research Institute
346
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Catalina Research Institute
19
mi
from 91732
Chino, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Catalina Research Institute
19
mi
from 91732
Chino, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
ATP Clinical Research, Inc.
28
mi
from 91732
Costa Mesa, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
ATP Clinical Research, Inc.
28
mi
from 91732
Costa Mesa, CA
Click here to add this to my saved trials